FTC Reports Significant Markups by Big 3 PBMs — $7.3 Billion Revenue from Drug Markups
RedMap Risk Score
80/100
CRITICAL RISK
Risk Signal Summary
The FTC's second interim report reveals that the Big 3 pharmacy benefit managers (PBMs) charged excessive markups on specialty generic drugs, generating over $7.3 billion in revenue from 2017-2022. This report highlights the impact on drug costs for patients and healthcare plans.
Why This Matters
Governance and compliance anomalies in organizations managing public funds or charitable assets directly affect donors, beneficiaries, and taxpayers. The risk indicators identified in this report warrant further scrutiny by regulators, donors, and oversight bodies.
Create a free account
Unlimited access to all articles · No daily limit
No credit card · Instant access
Multiple related entities detected
🔒 Caremark Rx, LLC, Express Scripts, Inc., Optumrx, Inc. has potential risk indicators with connected organizations. Unlock full network analysis.
Sign up free to unlock →Disclaimer: This report identifies risk indicators and unusual financial patterns based on publicly available IRS Form 990 data and government enforcement records. It does not assert fraud, criminal conduct, or legal violations. All findings are for informational purposes only and should not be construed as legal or financial advice.
Share this finding
You just analyzed Caremark Rx, LLC, Express Scripts, Inc., Optumrx, Inc. — Risk Score 80/100, $7.3B involved. Share this with your network.
Post text is pre-formatted for maximum reach — you can edit before posting.
Discover more risk signals across the USA.